Literature DB >> 15988036

Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.

Carolyn V Ustach1, Hyeong-Reh Choi Kim.   

Abstract

Platelet-derived growth factor (PDGF) protein family members are potent mitogens and chemoattractants for mesenchymal cells. The classic PDGF ligands A and B are single-domain protein chains which are secreted as active dimers capable of activating their cognate PDGF receptors (PDGFRs). In contrast to PDGFs A and B, PDGF D contains an N-terminal complement subcomponent C1r/C1s, Uegf, and Bmp1 (CUB) domain and a C-terminal PDGF domain. PDGF D must undergo extracellular proteolytic processing, separating the CUB domain from the PDGF domain, before the PDGF domain can stimulate beta-PDGFR-mediated cell signal transduction. Here, we report that prostate carcinoma cells LNCaP and PC3 autoactivate latent full-length PDGF D into its active form under serum-independent conditions and that this autoactivation is inhibited by PAI-1, a urokinase plasminogen activator (uPA)/tissue plasminogen activator (tPA) inhibitor. Interestingly, uPA, but not the closely related protease tPA, is capable of processing recombinant latent PDGF DD into the active form. We identify the uPA cleavage site between the CUB and PDGF domains of the full-length PDGF D by mutational analysis and show that PDGF D and uPA colocalize in human prostate carcinoma. This evidence provides a direct link between uPA- and PDGF D-mediated cell signaling, which may contribute to the progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988036      PMCID: PMC1168822          DOI: 10.1128/MCB.25.14.6279-6288.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  42 in total

1.  Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase.

Authors:  S H Ke; G S Coombs; K Tachias; M Navre; D R Corey; E L Madison
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

Review 2.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

3.  Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia.

Authors:  K Fudge; D G Bostwick; M E Stearns
Journal:  Prostate       Date:  1996-11       Impact factor: 4.104

4.  Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.

Authors:  S G Eckhardt; J Rizzo; K R Sweeney; G Cropp; S D Baker; M A Kraynak; J G Kuhn; M A Villalona-Calero; L Hammond; G Weiss; A Thurman; L Smith; R Drengler; J R Eckardt; J Moczygemba; A L Hannah; D D Von Hoff; E K Rowinsky
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

5.  Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

Authors:  T R Golub; G F Barker; M Lovett; D G Gilliland
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

Review 6.  Platelet-derived growth factor in human glioma.

Authors:  B Westermark; C H Heldin; M Nistér
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

7.  Urokinase-type plasminogen activator expression in human prostate carcinomas.

Authors:  P J Van Veldhuizen; R Sadasivan; R Cherian; A Wyatt
Journal:  Am J Med Sci       Date:  1996-07       Impact factor: 2.378

8.  Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.

Authors:  L Naldini; E Vigna; A Bardelli; A Follenzi; F Galimi; P M Comoglio
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

9.  The v-sis oncogene product but not platelet-derived growth factor (PDGF) A homodimers activate PDGF alpha and beta receptors intracellularly and initiate cellular transformation.

Authors:  B E Bejcek; R M Hoffman; D Lipps; D Y Li; C A Mitchell; P W Majerus; T F Deuel
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

10.  Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas.

Authors:  K Fudge; C Y Wang; M E Stearns
Journal:  Mod Pathol       Date:  1994-06       Impact factor: 7.842

View more
  40 in total

Review 1.  Emerging roles of PDGF-D signaling pathway in tumor development and progression.

Authors:  Zhiwei Wang; Aamir Ahmad; Yiwei Li; Dejuan Kong; Asfar S Azmi; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-04-28

2.  A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.

Authors:  Carolyn V Ustach; Wei Huang; M Katie Conley-LaComb; Chen-Yong Lin; Mingxin Che; Judith Abrams; Hyeong-Reh Choi Kim
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.

Authors:  Zhiwei Wang; Shadan Ali; Sanjeev Banerjee; Bin Bao; Yiwei Li; Asfar S Azmi; Murray Korc; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2013-03       Impact factor: 6.384

Review 4.  Circadian rhythm disruption in cancer biology.

Authors:  Christos Savvidis; Michael Koutsilieris
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

5.  Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

Authors:  Abdo J Najy; Young Suk Jung; Joshua J Won; M Katie Conley-LaComb; Allen Saliganan; Chong Jai Kim; Elisabeth Heath; Michael L Cher; R Daniel Bonfil; Hyeong-Reh Choi Kim
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

6.  Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Authors:  Newton J Hurst; Abdo J Najy; Carolyn V Ustach; Lisa Movilla; Hyeong-Reh Choi Kim
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

7.  PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Authors:  M Katie Conley-LaComb; Wei Huang; Shihua Wang; Dongping Shi; Young Suk Jung; Abdo Najy; Rafael Fridman; R Daniel Bonfil; Michael L Cher; Yong Q Chen; Hyeong-Reh Choi Kim
Journal:  Am J Pathol       Date:  2011-12-28       Impact factor: 4.307

Review 8.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

9.  An oncogenic activity of PDGF-C and its splice variant in human breast cancer.

Authors:  Alyssa Bottrell; Yong Hong Meng; Abdo J Najy; Newton Hurst; Seongho Kim; Chong Jai Kim; Eun-Sook Kim; Aree Moon; Eun Joo Kim; So Yeon Park; Hyeong-Reh Choi Kim
Journal:  Growth Factors       Date:  2019-09-23       Impact factor: 2.511

10.  The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.

Authors:  Peter Paximadis; Abdo J Najy; Michael Snyder; Hyeong-Reh Kim
Journal:  Prostate       Date:  2016-01-06       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.